RT Journal Article
SR Electronic
T1 Effect of Wearing Glasses for Prevention of SARS-CoV-2 on Visits to Health Care Providers - Additional Results from a Randomized Controlled Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.29.24311868
DO 10.1101/2024.08.29.24311868
A1 Elgersma, Ingeborg Hess
A1 Elstrøm, Petter
A1 Hemkens, Lars G.
A1 Helleve, Arnfinn
A1 Kacelnik, Oliver
A1 Fretheim, Atle
YR 2024
UL http://medrxiv.org/content/early/2024/08/29/2024.08.29.24311868.abstract
AB We previously published results of a pragmatic randomized trial with 3717 participants in Norway that assessed the effect of wearing glasses on the risk of being infected with SARS-CoV-2 and other respiratory infections. Here we present unpublished findings on pre-specified secondary endpoints relying on routinely collected data from Norwegian health registries: Visits to health care providers for any cause (within 21 days), for respiratory symptoms (day 3-28), and for injuries (within 21 days).1469 participants (39.5%) visited a health care provider for any cause at least once. There was no statistically significant difference between groups, with 39.9.% of participants wearing glasses versus 39.1% in the control group received primary or specialist care (absolute risk difference 0.76%; 95% CI, -2.4% to 3.9%; relative risk 1.02; 95% CI, 0.94 to 1.10).Similarly, there was no statistically significant difference in visits due to respiratory symptoms (326 participants; 9.1% versus 8.4%; absolute risk difference 0.71%; 95% CI, -1.1% to 2.5%; relative risk 1.08; 95% CI, 0.88 to 1.33).There were 3 participants having visited primary or specialist care and having an injury registered in a registry for injuries, the difference between groups not statistically significant. The difference between participants in the proportion of visits for injury related diagnoses was nominally statistically significant (1.3% versus 0.7%; absolute risk difference 0.7%; 95% CI, 0.01% to 1.3%; relative risk 1.94; 95% CI, 1.01 to 3.89).The study underscores the potential of utilizing registry-based outcomes for randomized evaluations of public health measures for infection control.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05217797Clinical Protocols https://doi.org/10.1101/2022.07.31.22278223 Funding Statementthe Centre for Epidemic Interventions Research, Norwegian Institute of Public HealthAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the Regional Ethics Committee of South-East Norway (reference no. 428685)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets generated and/or analysed during the current study are not publicly available due to data protection reasons but deidentified participant data are available in from the corresponding author on reasonable request.